À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾

ÌõÄ¿µÄ

À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾ÈëÑ¡ “2023 ÄêÈËÁ¦×ʱ¾ÊÂÐä½± “ºÍ “ÈËÁ¦×ʱ¾¹ÜÀí½ðÖʽ±”

À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾Öêʽ»áÉçÐû²¼ÈëÑ¡ÓÉHR Technology Consortium¡¢HR Research Institute (ProFuture Inc.)ºÍMS&AD InterRisk Research & Consulting, Inc.ÁªºÏ¿ªÕ¹µÄ¡°2023ÈËÁ¦×ʱ¾ÊӲ족ÖÐÈëÑ¡”2023 ÄêÈËÁ¦×ʱ¾ÊÂÐä½± “ºÍ “ÈËÁ¦×ʱ¾¹ÜÀí½ðÖʽ±”¡£

ÔÙÐøÐÂƪ¡ª¡ªÎ÷°²½»Í¨´óѧҩѧԺ¾ÙÐÐÀ´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾Öйú½±½Ìѧ½ð°ä½±ÒÇʽ

2024Äê1ÔÂ16ÈÕ£¬ÓÉÀ´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾¾èÔù£¬Î÷°²½»Í¨´óѧҩѧԺÖ÷°ìµÄ2023Äê¶È¡°À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾Öйú½±½Ìѧ½ð¡± […]

,

À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾ÔÚÈÕ±¾Ìá½»ÓÃÓÚÖÎÁƼ¡Î®Ëõ²àË÷Ó²»¯Ö¢µÄ³¬¸ß¼ÁÁ¿¼×îÜ°·ÖƼÁµÄÐÂÒ©ÉêÇë

À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾ÒÑÓÚ1ÔÂ26ÈÕÏòÈÕ±¾Ò½Ò©Æ·ºÍÒ½ÁÆÆ÷е¹ÜÀí¾Ö£¨PDMA£©Ìá½»Á˳¬¸ß¼ÁÁ¿¼×îÜ°·µÄÐÂÒ©ÉêÇ루NDA£©£¨¿ª·¢´úÂ룺E0302£©£¬¸ÃÒ©ÓÃÓÚÖÎÁƼ¡Î®ËõÐÔ¼¹Ëè²àË÷Ó²»¯Ö¢£¨ALS£©¡£

À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾ÖÎÁÆÍ´·çÐÂÒ©¡¸¶àÌæŵÀס¹ÔÚÖйúÉ걨ÉÏÊÐ

2024Äê1ÔÂ22ÈÕ£¬Öйú¹ú¼ÒÒ©Æ·¼à¶½¹ÜÀí¾ÖÒ©Æ·ÉóÆÀÖÐÐÄ£¨CDE£©¹ÙÍø¹«Ê¾£¬À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾ÖйúÒÔ×¢²á·ÖÀà5.1ÀàÉ걨µÄ¶àÌæŵÀ×ƬÉÏÊÐÉêÇëÒÑ»ñµÃÊÜÀí¡£¶àÌæŵÀ×Ƭ£¨Dotinurad£¬ÉÌÆ·Ãû£ºÓÅÀÖ˼£©ÊÇÒ»¿î´ÙÄòËáÅÅйҩ£¬´ËÇ°ÒѾ­ÓÚ2020ÄêÔÚÈÕ±¾ÉÏÊУ¬ÓÃÓÚÖÎÁƸßÄòËáѪ֢ºÍÍ´·ç¡£

À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾ÖйúÁ¬ÐøÎåÄêÈÙ»ñ¡°Öйú½Ü³ö¹ÍÖ÷¡±ÈÏÖ¤£¬ÒÔÈËΪ±¾´òÔì׿Խְ³¡»·¾³

2024Äê1ÔÂ18ÈÕ£¬È«Çò½Ü³ö¹ÍÖ÷µ÷Ñлú¹¹£¨Top Employers Institute£©Ðû²¼ÁË¡°2024Äê¶ÈÖйú½Ü³ö¹ÍÖ÷¡±°ñµ¥£¬À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾Öйúƾ½èÆäÆóÒµÎÄ»¯¡¢È˲ÅÕ½ÂÔ¡¢Ô±¹¤¾ì×¢¡¢Ð½³ê¸£ÀûÒÔ¼°¿ÉÁ¬ÐøÉú³¤µÈ·½ÃæµÄ׿ԽÌåÏÖ£¬ÒÔÎåÄêÀ´µÄ×î¸ßµÃ·Ö97.14%£¬Á¬ÐøµÚÎåÄêÈÙ»ñ´ËÏîÈÏÖ¤¡£

À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾µÚ°Ë´ÎÈëÑ¡È«Çò×î¿ÉÁ¬ÐøÉú³¤ÆóÒµ100Ç¿

À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾ÈëÑ¡ÓɼÓÄôóýÌåºÍͶ×Ê×Éѯ¹«Ë¾Corporate Knights, Inc.Ðû²¼µÄ2024ÄêÈ«Çò100¼Ò×î¿ÉÁ¬ÐøÉú³¤ÆóÒµ£¨Global 100£©£¬Î»ÁеÚ35¡£ÕâÊÇÀ´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾µÚ°Ë´ÎÉÏ°ñ£¬ÊÇÈ«ÇòÅÅÃû×î¸ßµÄÖÆÒ©ÆóÒµ£¬Ò²ÊÇÈ«Çò100Ç¿ÖÐÅÅÃû×î¸ßµÄÈÕ±¾ÆóÒµ¡£

°¢¶û´Äº£Ä¬²¡ÖÎÁÆÐÂÏ£Íû£¬È«ÇòÊ׿¶û´Äº£Ä¬²¡°ÐÏòÒ©ÀÖÒâ±£?£¨ÂØ¿¨Ä¹£©ÔÚÖйú»ñÅú

2024Äê1ÔÂ9ÈÕ£¬ÖйúÉϺ£¡ª¡ªÀ´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾Ðû²¼£¬°¢¶û´Äº£Ä¬²¡£¨ÏÂÎļò³Æ£ºAD£©´´ÐÂÖÎÁÆÒ©ÎïÀÖÒâ±£?£¨ÂØ¿¨Ä¹£©»ñ¹ú¼ÒÒ©Æ·¼à¶½¹ÜÀí¾Ö£¨NMPA£©Åú×¼Õýʽ½øÈëÖйú£¬ÓÃÓÚÖÎÁÆÓÉ°¢¶û´Äº£Ä¬²¡ÒýÆðµÄÇá¶ÈÈÏÖªÕÏ°­ºÍ°¢¶û´Äº£Ä¬²¡Çá¶È³Õ´ô¡£×÷ΪȫÇòÊ׸öÕë¶ÔAD²¡ÒòµÄÍ»ÆÆÐÔ°ÐÏòÒ©ÎÀÖÒâ±£?µÄ»ñÅú½«ÒýÁìADÖÎÁÆ¿çÈë¡°¶ÔÒòÖÎÁÆ¡±ÐÂʱ´ú£¬ÎªÖйúAD»¼ÕßÌṩ¸üÓÅÖÎÁÆÑ¡Ôñ¡£

ÂØ¿¨Ä¹ÔÚÖйú»ñÅúÓÃÓÚÖÎÁÆ°¢¶û´Äº£Ä¬²¡

À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾ºÍ²³½¡Ðû²¼£¬ÈËÔ´»¯¿¹¿ÉÈÜÐԦµí·ÛÑùÂÑ°×(A¦Â)µ¥¿Ë¡¿¹ÌåLEQEMBI? £¨ÂØ¿¨Ä¹£¬ÖÐÎÄÉÌÆ·Ãû£ºÀÖÒâ±£?£©ÔÚÖйú»ñÅú£¬ÓÃÓÚÖÎÁÆÓÉ°¢¶û´Äº£Ä¬²¡ÒýÆðµÄÇá¶ÈÈÏÖªÕÏ°­ºÍ°¢¶û´Äº£Ä¬²¡Çá¶È³Õ´ô¡£

À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾ÔÚÈÕ±¾Ìá½»ÓÃÓÚÖÎÁÆ FGFR2 »ùÒòÈںϵ¨µÀ°©µÄ¿¹°©Ò©Îï Tasurgratinib µÄÉÏÊÐÐí¿ÉÉêÇë

12ÔÂ18ÈÕ£¬ÓÉÀ´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾Ô­ÑеijÉÏËάϸ°ûÉú³¤Òò×Ó£¨FGF£©ÊÜÌ壨FGFR1¡¢FGFR2¡¢FGFR3£©Ñ¡ÔñÐÔÀÒ°±ËἤøÒÖÖƼÁ¡ª¡ªTasurgratinib£¨Í¨ÓÃÃû£¬¿ª·¢´úÂ룺E7090£©ÒÑÔÚÈÕ±¾Ìá½»ÉÏÊÐÐí¿ÉÉêÇë¡£¸ÃÒ©ÎïÓÃÓÚÖÎÁƾßÓÐFGFR2»ùÒòÈںϵĵ¨µÀ°©¡£ÔÚÈÕ±¾£¬ÒòTasurgratinib¿ÉÓÃÓÚÖÎÁÆFGFR2»ùÒòÈںϵIJ»ÐÐÇгýµ¨µÀ°©ÕâÖÖÓÐÇ°¾°µÄÊÊÓ¦Ö¢£¬ÒÑ»ñµÃºñÉúÀͶ¯Ê¡ (MHLW) µÄ¹Â¶ùÒ©È϶¨¡£ÔÚ´ËÖƶÈÏ£¬±¾´ÎÉêÇ뽫Êܵ½ÓÅÏÈÉó²é¡£

ADÐÂÒ©ÂØ¿¨Ä¹×¢ÉäÒº½«ÓÚ12ÔÂ20ÈÕÔÚÈÕ±¾ÉÏÊÐ

À´Àû¹ú¼Êw66¹Ù·½ÍøÕ¾ºÍ²³½¡Ðû²¼£¬ÈËÔ´»¯¿¹¿ÉÈÜÐԦµí·ÛÑùÂÑ°×(A¦Â)µ¥¿Ë¡¿¹ÌåLEQEMBI?£¨ÂØ¿¨Ä¹£©¾²Âö×¢É䣨200mg¡¢500mg£©½«ÓÚ12ÔÂ20ÈÕÔÚÈÕ±¾ÉÏÊУ¬²¢°´¼Æ»®ÁÐÈëÈÕ±¾¹úÃñ½¡¿µ±£ÏÕ£¨NHI£©Ò©Æ·¼Û¸ñĿ¼¡£

ÍøÕ¾µØͼ